Matching articles for "suzetrigine"

Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain

   
The Medical Letter on Drugs and Therapeutics • March 3, 2025;  (Issue 1723)
The FDA has approved suzetrigine (Journavx – Vertex), a selective sodium channel blocker, for oral treatment of moderate to severe acute pain in adults. Suzetrigine is the first sodium channel blocker to...
The FDA has approved suzetrigine (Journavx – Vertex), a selective sodium channel blocker, for oral treatment of moderate to severe acute pain in adults. Suzetrigine is the first sodium channel blocker to be approved in the US for this indication and the first oral nonopioid drug to be approved for treatment of pain in over 25 years.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):33-5 | Show Full IntroductionHide Full Introduction